| 项目 本报告期（元） 上年同期（元） 本报告期比上年同期增减（%） | | --- | | 营业收入 97,415,845.21 89,634,394.36 8.68% | 净利润下滑34.06%，盈利能力面临挑战 归属于上市公司股东的净利润为2662.67万元，而上年同期为4038.15万元，同比下降34.06%。净利润的大 幅下滑，无疑给公司的盈利能力敲响了警钟，后续需关注公司采取何种策略提升盈利水平。 2025年第一季度，烟台 正海生物 科技股份有限公司（以下简称"烟台正海生物"）的财务状况呈现出多维度 的变化。净利润的显著下滑与营业外收入的暴增形成鲜明对比，各项费用、资产负债以及现金流量等方面 也均有不同程度的变动。这些变化对于投资者而言，蕴含着诸多值得关注与分析的要点。 营收微增8.68%，市场拓展稳步推进 2025年第一季度，烟台正海生物营业收入为9741.58万元，较上年同期的8963.44万元增长了8.68%。这表明 公司在市场拓展方面取得了一定成效，业务规模有所扩大。 | 项目 本报告期（元） 上年同期（元） 本报告期比上年同期增减(%) | | --- | | 归属于上市公司股东的净利 ...

提示性公告 证券代码：300653 证券简称：正海生物 公告编号：2025-016 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 2025 年 4 月 21 日，烟台正海生物科技股份有限公司（以下简称"公司"） 第四届董事会第七次会议审议通过了《关于公司 2025 年第一季度报告的议案》。 为使投资者全面了解报告期内公司的经营情况和财务状况，公司 2025 年第一季 度报告于 2025 年 4 月 22 日在中国证监会指定信息披露网站巨潮资讯网 （http://www.cninfo.com.cn）上披露。 敬请投资者注意查阅。 特此公告。 烟台正海生物科技股份有限公司 董 事 会 2025 年 4 月 22 日 烟台正海生物科技股份有限公司 2025 年第一季度报告披露提示性公告 ...

监事会决议公告 证券代码：300653 证券简称：正海生物 公告编号：2025-019 烟台正海生物科技股份有限公司 第四届监事会第六次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、监事会会议召开情况 烟台正海生物科技股份有限公司（以下简称"公司"）第四届监事会第六次 会议于 2025 年 4 月 21 日以通讯方式召开，会议通知已于 2025 年 4 月 18 日以电 子邮件形式向全体监事发出。本次会议应到监事 3 人，实到 3 人，其中许月莉、 潘励山、宋广平以通讯方式出席会议，会议由许月莉女士主持。会议的出席人数、 召开和表决方式符合《中华人民共和国公司法》等法律法规及《烟台正海生物科 技股份有限公司章程》的相关规定，合法有效。 二、监事会会议审议情况 经与会监事认真审议，通过如下决议： 1、关于公司 2025 年第一季度报告的议案 经审核，监事会认为董事会编制和审核公司《2025 年第一季度报告》的程 序符合法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映 了公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏 ...

证券代码：300653 证券简称：正海生物 公告编号：2025-018 董事会决议公告 烟台正海生物科技股份有限公司 第四届董事会第七次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 烟台正海生物科技股份有限公司（以下简称"公司"）第四届董事会第七次 会议于 2025 年 4 月 21 日以通讯方式召开，会议通知已于 2025 年 4 月 18 日以电 子邮件形式向全体董事发出，本次会议应参会董事 9 人，实参会董事 9 人，其中 以通讯表决方式出席会议的人数为 9 人，分别为郭焕祥、Qun Dong、宋侃、赵 丽、张超、倪霆、宋希亮、王辉、李江华。会议由郭焕祥先生主持，监事许月莉、 潘励山、宋广平列席会议。会议出席人数、召开和表决方式符合《公司法》等法 律、法规及《公司章程》的相关规定，合法有效。 二、董事会会议审议情况 经与会董事研究，会议审议通过了如下决议： 1、关于公司 2025 年第一季度报告的议案 经与会董事表决，同意票：9 票，反对票：0 票，弃权票：0 票。同意票占 出席董事总票数的 100%，表决通过。 ...

正海生物（300653）公告，2025年第一季度营收为9741.58万元，同比增长8.68%；净利润为2662.67万 元，同比下降34.06%。 ...

Financial Performance - The company's revenue for Q1 2025 was ¥97,415,845.21, an increase of 8.68% compared to ¥89,634,394.36 in the same period last year[5] - Net profit attributable to shareholders decreased by 34.06% to ¥26,626,723.19 from ¥40,381,480.54 year-on-year[5] - The net profit excluding non-recurring gains and losses was ¥23,835,843.45, down 32.13% from ¥35,121,314.44 in the previous year[5] - Basic and diluted earnings per share decreased by 31.82% to ¥0.15 from ¥0.22 year-on-year[5] - Net profit for the current period was ¥26,626,723.19, a decrease of 34.1% from ¥40,381,480.54 in the previous period[22] Operating Costs and Expenses - Operating costs rose by 62.96% to ¥18,548,598.03 compared to ¥11,382,167.75 in the same period last year, primarily due to increased sales volume[9] - Sales expenses increased by 52.42% to ¥32,679,942.53 from ¥21,440,976.21 year-on-year, attributed to targeted marketing efforts[9] - Total operating costs increased to ¥69,470,342.54, up 45.2% from ¥47,887,035.39 in the previous period[21] - Research and development expenses rose to ¥10,539,502.19, compared to ¥8,241,068.59 in the previous period, reflecting a 28% increase[21] Cash Flow and Liquidity - Operating cash flow increased by 6.97% to ¥38,947,811.13 compared to ¥36,410,107.03 in the same period last year[5] - Cash flow from operating activities was not detailed in the provided content, but is critical for assessing liquidity and operational efficiency[23] - Operating cash inflow for the current period was $113,607,783.91, up from $92,635,155.96 in the previous period, representing a growth of approximately 22.6%[24] - Net cash flow from operating activities increased to $38,947,811.13 from $36,410,107.03, reflecting a rise of about 6.9%[24] - Cash and cash equivalents decreased from 116,837,501.64 CNY to 66,588,190.74 CNY, a decline of approximately 43%[17] Assets and Equity - Total assets at the end of the reporting period were ¥1,011,700,820.47, a 3.22% increase from ¥980,113,621.99 at the end of the previous year[5] - Shareholders' equity attributable to the parent company increased by 3.00% to ¥915,410,854.93 from ¥888,784,131.74 at the end of the previous year[5] - Total current assets increased from 712,700,493.26 CNY to 749,093,740.23 CNY, an increase of about 5.1%[17] - Total liabilities rose to ¥96,289,965.54, compared to ¥91,329,490.25 in the previous period, marking a 5.3% increase[19] - Total equity attributable to shareholders increased to ¥915,410,854.93 from ¥888,784,131.74 in the previous period[19] Shareholder Information - The total number of common shareholders at the end of the reporting period is 16,966[11] - The largest shareholder, Mibohai, holds 33.87% of shares, totaling 60,961,500 shares, with 16,000,000 shares pledged[11] - Longwood Biotechnologies Inc. is the second-largest shareholder, holding 7.67% of shares, totaling 13,811,874 shares[11] - The company has no preferred shareholders as of the reporting period[13] - The total number of shareholders with voting rights restored for preferred shares is 0[11] Inventory and Fixed Assets - The total inventory decreased from 35,183,154.31 CNY to 28,257,139.60 CNY, a decline of approximately 19.7%[17] - The total fixed assets decreased from 228,744,485.59 CNY to 224,843,942.51 CNY, a decline of about 1.7%[17] Other Financial Activities - The company reported a significant increase in other operating income, which rose by 2611.34% to ¥29,840.47 from ¥1,100.58 in the previous year[9] - Cash inflow from investment activities decreased to $293,907,815.97 from $376,006,483.59, a decline of approximately 21.9%[25] - Net cash flow from investment activities was negative at -$88,226,053.24, compared to a positive $75,754,219.36 in the previous period[25] - The company did not report any cash inflow from financing activities during this period[25] - The first quarter report was not audited, indicating that the financial data may be subject to further review[26]

注销全资子公司 证券代码：300653 证券简称：正海生物 公告编号：2025-015 烟台正海生物科技股份有限公司 关于全资子公司注销完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 烟台正海生物科技股份有限公司（以下简称"公司"）于2024年10月21日召 开第四届董事会第五次会议，同意注销全资子公司苏州正海生物技术有限公司 （以下简称"苏州正海"），具体内容详见公司2024年10月23日在巨潮资讯网 （www.cninfo.com.cn）披露的《关于注销全资子公司的公告》（公告编号： 2024-070）、《第四届董事会第五次会议决议公告》（公告编号：2024-068）。 2025 年 4 月 16 日 目前，公司已收到苏州工业园区行政审批局核发的《登记通知书》，苏州正 海的清税、注销登记、银行结算账户销户等相关注销手续已全部办理完毕。本次 注销完成后，苏州正海将不再纳入公司合并报表范围，不会对公司的生产经营及 财务状况产生重大影响。 特此公告。 烟台正海生物科技股份有限公司 董 事 会 ...

证券代码：300653 证券简称：正海生物 烟台正海生物科技股份有限公司 投资者关系活动记录表 编号：2025003 | | | □特定对象调研 □媒体采访 | | □分析师会议 | | | --- | --- | --- | --- | --- | --- | | 投资者关系 活动类别 | | □新闻发布会 □业绩说明会 | | □路演活动 | | | | | □现场参观 √其他 | 电话会 | | | | 参与单位名 | | 东北证券 刘宇腾、叶菁、方心宇；中金公司 | | 朱言音；华创证券 | 陈 | | 称及人员 姓名 | | 俊威；国盛证券 王震；平安证券 | 叶寅、裴晓鹏；西部证券 | | 陆伏葳； | | | | 华泰证券 孔垂岩等 位参会人员 97 | | | | | 时 | 间 | 2025 年 4 月 15 日 | | | | | 地 | 点 | 线上会议 | | | | | 上市公司接 | | 副总经理、董事会秘书兼财务总监：赵丽女士 | | | | | 待人员姓名 | | 董事会办公室经理：王安琪女士 | | | | 投资者关系活动主要内容 一、公司 2023 年经营情况介绍 2024 ...

Core Viewpoint - Zhenghai Biological's 2024 annual report reveals significant challenges, with a notable decline in both revenue and profit due to centralized procurement policies impacting key products [1][2]. Financial Performance - The company achieved an annual revenue of 363 million yuan, a year-on-year decrease of 12.19% [1]. - The net profit attributable to shareholders was 135 million yuan, down 29.49% year-on-year [1]. - The net profit after deducting non-recurring items was 113 million yuan, with a decline of 32.59%, marking the largest drop in five years [1]. - Quarterly performance showed a 17.83% decline in Q1 revenue, a reduced decline of 6.1% in Q2, and overall improvement in the second half, but not enough to reverse the annual downturn [1]. Impact of Centralized Procurement Policy - Centralized procurement policies have significantly affected the company's core products: oral repair membranes (48.3% of revenue) and absorbable dura mater patches (35.2% of revenue) [1]. - The price drop for dura mater patches reached 83.46% due to a six-province alliance, severely impacting revenue [1]. - The oral repair membrane's gross margin decreased by 2.73 percentage points, contributing to the decline in net profit [1][2]. Cost Control and Profitability - Despite revenue pressures, the company maintained a gross margin above 86%, with a slight year-on-year decrease of 3.96 percentage points [2]. - The net profit margin was 43.45%, still above the industry average, despite an 11.2% year-on-year decline [2]. - The company successfully mitigated some impacts of price reductions through supply chain optimization, showcasing strong cost control capabilities [2][4]. Cash Flow and Shareholder Returns - Operating cash flow net amount decreased by 7.77% year-on-year but remained positive, supporting dividend payments [2]. - Cumulative dividends since the company's listing reached 536 million yuan, with a dividend financing ratio of 2.29, indicating a strong commitment to shareholder returns [2]. Innovation and New Product Development - The company has been overly reliant on traditional products, with R&D expenses not significantly increasing as a percentage of revenue [3]. - New products like "Haiyu" active biological bone, which is the first domestic bone filling material containing rhBMP-2, represent a key opportunity for growth [3][4]. - The successful launch of "Haiyu" and ongoing projects like calcium silicate biological ceramic bone repair materials and breast patches could provide new revenue streams [3][4]. Strategic Adjustments - The company is adjusting its market strategy in response to centralized procurement pressures, including optimizing the supply chain and reducing sales expenses [4]. - The potential expansion of centralized procurement for oral repair membranes and dura mater patches in 2025 indicates ongoing pricing pressures [5]. - Despite a stock price decline of over 50% since 2023, the company announced a share buyback plan of 25 to 50 million yuan, reflecting management's confidence in long-term value [5].

证券研究报告 正海生物 (300653 CH) 2024 年销售/管理/研发/财务费用率分别为 32.93%/7.79%/10.88%/-0.14%， 同比+7.22/+1.28/+0.23/+0.00pct。公司持续加强销售费用投入，销售费用 率相应提高。2024 年毛利率为 87.64%，同比-2.26pct，我们认为主因市场 竞争加剧及集采等影响下公司产品毛利率有所下降。 有望受益消费医疗恢复，维持"买入"评级 业绩增速承压，期待后续恢复 | 华泰研究 | | | 年报点评 | | --- | --- | --- | --- | | 2025 年 | 4 月 | 15 日│中国内地 | 医疗器械 | 公司 2024 年收入/归母净利润/扣非归母净利润 3.63/1.35/1.13 亿元，同比 -12.2%/-29.5%/-32.6% ； 4Q24 收 入 / 归 母 净 利 润 / 扣 非 归 母 净 利 润 0.72/0.10/0.05 亿元，同比-21.8%/-77.5%/-75.7%。24 年业绩低于我们预期， 我们认为主要由于消费医疗需求尚未完全恢复，手术量增长放缓，以及脑膜 产品受集采影响，导 ...